These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 27052387)

  • 21. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
    Reich K; Burden AD; Eaton JN; Hawkins NS
    Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
    Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
    Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study.
    Rigopoulos D; Gregoriou S; Makris M; Ioannides D
    Dermatology; 2011; 223(4):325-9. PubMed ID: 22134046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis.
    Au SC; Goldminz AM; Kim N; Dumont N; Michelon M; Volf E; Hession M; Lizzul PF; Andrews ID; Kerensky T; Wang A; Yaniv S; Gottlieb AB
    J Dermatolog Treat; 2013 Jun; 24(3):179-87. PubMed ID: 22390688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Usefulness and correlation with clinical response of serum ustekinumab levels measured at 6 weeks versus 12 weeks.
    Toro-Montecinos M; Ballescá F; Ferrandiz C; Teniente-Serra A; Martinez-Caceres E; Carrascosa JM
    J Dermatolog Treat; 2019 Feb; 30(1):35-39. PubMed ID: 29683393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry.
    Egeberg A; Iversen L; Gniadecki R; Hvid L; Dam TN; Bryld LE; Skov L
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1183-1187. PubMed ID: 28273375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis.
    Rouse NC; Farhangian ME; Wehausen B; Feldman SR
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):877-84. PubMed ID: 26488186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spotlight on ustekinumab in moderate to severe plaque psoriasis.
    Croxtall JD
    Am J Clin Dermatol; 2012 Apr; 13(2):135-7. PubMed ID: 22201419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.
    Rich P; Bourcier M; Sofen H; Fakharzadeh S; Wasfi Y; Wang Y; Kerkmann U; Ghislain PD; Poulin Y;
    Br J Dermatol; 2014 Feb; 170(2):398-407. PubMed ID: 24117389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient reported health outcomes and non-adherence in psoriasis patients receiving adalimumab or ustekinumab for moderate to severe plaque psoriasis.
    Goren A; Carter C; Lee S
    J Dermatolog Treat; 2016; 27(1):43-50. PubMed ID: 26088404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience.
    Chiricozzi A; Conti A; Burlando M; Odorici G; Gaiani F; Panduri S; Malagoli P
    Dermatology; 2019; 235(3):213-218. PubMed ID: 30928971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement of depressive symptoms in patients with moderate-to-severe psoriasis treated with ustekinumab: an open label trial validated using beck depression inventory, Hamilton depression rating scale measures and
    Kim SJ; Park MY; Pak K; Han J; Kim GW; Kim HS; Ko HC; Kim MB; Kim BS
    J Dermatolog Treat; 2018 Dec; 29(8):761-768. PubMed ID: 29658378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28508536
    [No Abstract]   [Full Text] [Related]  

  • 34. Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis.
    Augustin M; Blome C; Paul C; Puig L; Luger T; Lambert J; Chimenti S; Girolomoni G; Kragballe K; Naessens D; Bergmans P; Smirnov P; Barker J; Reich K
    J Eur Acad Dermatol Venereol; 2017 Feb; 31(2):294-303. PubMed ID: 27515070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study.
    Papp KA; Sundaram M; Bao Y; Williams DA; Gu Y; Signorovitch JE; Wang Y; Valdes JM; Mulani PM
    J Eur Acad Dermatol Venereol; 2014 Jun; 28(6):790-8. PubMed ID: 23679896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients.
    Sorensen EP; Fanucci KA; Saraiya A; Volf E; Au SC; Argobi Y; Mansfield R; Gottlieb AB
    J Drugs Dermatol; 2015 Aug; 14(8):893-8. PubMed ID: 26267736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
    Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
    Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
    J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
    Wong IT; Shojania K; Dutz J; Tsao NW
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):153-66. PubMed ID: 26681527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study.
    Savage L; Goodfield M; Horton L; Watad A; Hensor E; Emery P; Wakefield R; Wittmann M; McGonagle D
    Arthritis Rheumatol; 2019 Apr; 71(4):626-631. PubMed ID: 30468001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.